TwinBeech Capital’s Heron Therapeutics HRTX Stock Holding History

TwinBeech Capital’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-398,673	Closed	-$1.11M	–	714
2022 Q2	$1.11M	Buy	+398,673	New	+$1.6M	0.05%	308
2021 Q4	–	Sell	-18,167	Closed	-$194K	–	668
2021 Q3	$194K	Buy	+18,167	New	+$221K	0.01%	536
2020 Q3	–	Sell	-21,636	Closed	-$318K	–	498
2020 Q2	$318K	Buy	+21,636	New	+$355K	0.07%	284

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

TwinBeech Capital's HRTX Position: Q3 2022 in Review

TwinBeech Capital sold out of Heron Therapeutics (HRTX) in Q3 2022, closing a stake of 398,673 shares — an estimated $1.11M sold.

TwinBeech Capital first reported a position in HRTX in Q2 2020 and held it in 3 quarters. The position peaked at $1.11M in Q2 2022. 186 funds tracked by Wall St. Rank hold HRTX as of Q3 2022.

TwinBeech Capital reported no remaining Heron Therapeutics position as of Q3 2022 after selling out during the quarter.
TwinBeech Capital sold 398,673 Heron Therapeutics shares in Q3 2022, an estimated $1.11M.
TwinBeech Capital first reported a position in Heron Therapeutics in Q2 2020 and held it in 3 quarters.
TwinBeech Capital's Heron Therapeutics position peaked at $1.11M in Q2 2022.
186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2022.

Based on TwinBeech Capital's 13F filing for Q3 2022, filed 14 Nov 2022.